Session: 901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research, Health outcomes research
Methods: We developed a threshold decision model incorporating VTE recurrence risk, AC efficacy, bleeding risks, and patient values and preferences (V&P). Key parameters included:
- VTE risk: 10% in year 1, then 5%/year
- AC efficacy: Relative Risk Reduction (RRR) = 0.85 [0.77 to 0.9]
- Bleeding risk: Low (0.5%/year) and High (1.5%/year)
- Major bleeding on AC: RR 2.17
- Relative value (RV): patient's weighting of VTE vs. bleeding risk
Results: The model calculates a threshold probability (T) at which AC benefits equal bleeding harms. AC is recommended when the probability of VTE without treatment (Pr(VTE)) exceeds the risk of bleeding. In most scenarios, the 10 Pr(VTE) consistently exceeded T, favoring long-term AC. This held true across various RV assumptions (RV=0.5, 1, 2) for both low and high bleeding risk scenarios. The only exception was in the high bleeding risk, worst-case scenario, where patients valuing avoiding bleeding twice as much as VTE (RV=2) might opt against long-term AC.
Conclusions: Based on current evidence of AC efficacy, bleeding risks, and estimated VTE recurrence rates, long-term AC appears to be the optimal management strategy for most patients with unprovoked VTE. Only in cases of high bleeding risk combined with strong patient preference for avoiding bleeding (RV>2) might discontinuation of AC be considered.
This model provides a framework for personalized decision-making, considering individual patient risks and preferences in determining the optimal duration of AC for unprovoked VTE.
Disclosures: Youkhana: HEMA Biologics: Honoraria.
See more of: Oral and Poster Abstracts